Stocks · News reference
Jefferies Upgrades Minerva Neurosciences to Buy, Raises Price Target to $10
Jefferies analyst Biren Amin upgrades Minerva Neurosciences (NASDAQ:NERV) from Hold to Buy and raises the price target from $7.5 to $10.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 14, 2026, 12:41 PM
- Checked
- Aug 14, 2026, 12:41 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
This Capricor Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Wall Street analysts revised their ratings for top stocks. Visit benzinga.com/analyst-stock-ratings for all changes, including upgrades and downgrades.
Read original at benzingaMinerva Neurosciences Q2 Adj. EPS $(0.10) Beats $(0.12) Estimate
Minerva Neurosciences (NASDAQ:NERV) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.12) by 9.09 percent. This is a 76.74 percent increase over losses of $(0.43) per share
Read original at benzinga